RxDoctor Payments Data

George Zureikat, MD

Pediatric Critical Care Medicine · Flint, MINPI 1891765426

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $129,337 of the $172,676 with a category attached, or 74.9%. Jazz Pharmaceuticals Inc. accounts for 64.7% of it on its own, with 21 other manufacturers making up the rest. Among pediatric critical care medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$172,676in general payments, 2019–2025

Across 503 payments — averaging $343.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$112K
  • Axsome Therapeutics, Inc.$25K
  • Harmony Biosciences LLC$16K
  • Idorsia Pharmaceuticals US Inc$15K
  • Inspire Medical Systems, Inc.$2K
  • Amgen$664
  • plus $2K from 16 others

What the payments were for

  • Consulting fees$16,78810%
  • Speaking & faculty fees$129,33775%
  • Travel & lodging$13,1978%
  • Food & beverage$12,8467%
  • Education$5080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$172,676 in reported general payments places this provider in the 95th percentile of 43 pediatric critical care medicine providers in Michigan.

See all pediatric critical care medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$84,715
Medicare patients
308
Services billed
714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SunosiSolriamfetol Hcl12$10,033
Modafinil48$6,260
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine19$763
Temazepam78$573
Trazodone Hcl70$556
Zolpidem Tartrate96$436
Clonazepam90$318
Pramipexole DihydrochloridePramipexole Di-Hcl30$271
Montelukast Sodium13$128
Gabapentin16$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Axsome Therapeutics, Inc.Sunosi$25,238$10,03312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 pediatric critical care medicine providers in Michigan.

Other pediatric critical care medicine in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →